CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 63 enrolled
Drug / intervention
Cisplatin +8 moredrug
Likely dose
Cisplatin 100 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03621696
NCT03621696Phase 2Completed

Phase II Trial of Surgery Followed by Risk-Directed Post-Operative Adjuvant Therapy for HPV-Related Oropharynx Squamous Cell Carcinoma: "The Minimalist Trial (MINT)"

Washington University School of Medicine·interventional·Posted Aug 8, 2018·Updated Apr 21, 2026

In Brief

A Phase 2 clinical trial evaluating Cisplatin, Intensity modulated radiation therapy, and 7 other interventions for HPV Related Oropharyngeal Squamous Cell Carcinoma. Completed, enrolled 63 participants across 1 site.

Detailed Summary

The overarching goal of the MINT trial is to reduce treatment-related toxicity while maintaining efficacy. Patients with HPV-related oropharyngeal squamous cell carcinoma (OPSCC) will undergo resection of the primary tumor site and involved/at risk regional neck nodes.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
20192020202120222023202420252026
First PostedAug 8, 2018
Enrollment StartOct 23, 2018
Primary CompletionMar 10, 2021
Study CompletionMar 17, 2026
TodayJul 2, 2026
Enrollment to primary: 2.4 yearsPosted 7.9 years ago

Interventions

Cisplatindrug

-100 mg/m\^2 intravenous push bolus (IVPB)

Intensity modulated radiation therapyradiation

-IMRT or IMPT can be used

Intensity modulated proton therapyradiation

-IMRT or IMPT can be used

Surgeryprocedure

-Standard of care

FACT-H&Nother

-Baseline, interim assessment (14-42 days post-surgery), day 1 of radiation, day 21 of radiation, day 36 of radiation, 6 weeks after completion of adjuvant therapy, 4 months after the completion of adjuvant therapy, 6 months after the completion of adjuvant therapy, 12 months after the completion of adjuvant therapy, and 24 months after completion of adjuvant therapy

MD Anderson Dysphagia Inventoryother

-Baseline, interim assessment (14-42 days post-surgery), day 1 of radiation, day 21 of radiation, day 36 of radiation, 6 weeks after completion of adjuvant therapy, 4 months after the completion of adjuvant therapy, 6 months after the completion of adjuvant therapy, 12 months after the completion of adjuvant therapy, and 24 months after completion of adjuvant therapy

University of Michigan Xerostomia Indexother

-Baseline, interim assessment (14-42 days post-surgery), day 1 of radiation, day 21 of radiation, day 36 of radiation, 6 weeks after completion of adjuvant therapy, 4 months after the completion of adjuvant therapy, 6 months after the completion of adjuvant therapy, 12 months after the completion of adjuvant therapy, and 24 months after completion of adjuvant therapy

Scale of Subjective Total Taste Acuityother

-Baseline, interim assessment (14-42 days post-surgery), day 1 of radiation, day 21 of radiation, day 36 of radiation, 6 weeks after completion of adjuvant therapy, 4 months after the completion of adjuvant therapy, 6 months after the completion of adjuvant therapy, 12 months after the completion of adjuvant therapy, and 24 months after completion of adjuvant therapy

Neck Dissection Impairment Indexother

-Baseline, interim assessment (14-42 days post-surgery), day 1 of radiation, day 21 of radiation, day 36 of radiation, 6 weeks after completion of adjuvant therapy, 4 months after the completion of adjuvant therapy, 6 months after the completion of adjuvant therapy, 12 months after the completion of adjuvant therapy, and 24 months after completion of adjuvant therapy